Unicycive Therapeutics宣布CEO将于9月15日在H.C. Wainwright第28届全球投资大会上进行演讲

这是一条例行的投资者会议演讲公告，不含任何新增实质信息。投资大会演讲是上市公司常规IR活动，不构成可交易催化。无论Web、KB还是行情查询都不可能改变不做的结论。

📄 原文GlobeNewswire All Public Companies↗ 原文

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage bio…

不做 Unicycive Therapeutics（UNCY.US）

例行投资大会演讲公告，不含任何新增实质信息（无临床数据、无监管进展、无业务发展），不构成可交易催化

展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)

研究档案

结论摘要

Unicycive Therapeutics通过GlobeNewswire发布了一条标准IR公告，宣布CEO将于2026年9月15日在H.C. Wainwright年度投资大会上演讲。公告全文未包含任何新的临床数据、监管审批进展、商业合作、财务指引或其他实质性业务信息。投资大会演讲是所有上市公司日常进行的投资者关系活动，不构成独立的价格催化。无交易方向，无可交易edge。

🔎 新鲜度:最早出现 2026-09-01 · 扩散 low · price-in 风险 low ↗

先例如何影响了这次决策

对本次决策的影响:无先例可用，但事件本身无催化性质，不影响AVOID结论

方向:不适用——例行会议演讲公告无历史先例可参考

涨幅量级:不适用

形态:不适用

工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0

search_processed_events 成功 stock_tools HTTP · 945 ms
{"result": "search_processed_events:agent query=`uncy conference presentation september 2026 | unicycive therapeutics h.c. wainwright conference presentation`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 61.7/72 小时、2087 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"}

原文全文

展开原文 · 1,487 字

LOS ALTOS, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 11 a.m. ET.
A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section:
Events and Presentations
.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit
Unicycive.com
and follow us on
LinkedIn
and
X
.
Investor Contact:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Unicycive Therapeutics
media@unicycive.com
SOURCE: Unicycive Therapeutics, Inc.

决策记录链 · 只追加

每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。

这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。